SELUTION DeNovo Trial Results
The SELUTION DeNovo randomized clinical trial, presented at TCT 2025 in San Francisco, USA, demonstrated non-inferiority of a drug-eluting balloon to standard-of-care for in-stent restenosis.
A percutaneous coronary intervention (PCI) strategy using the SELUTION SLR sirolimus-eluting balloon (SEB) with provisional stenting was found to be non-inferior to the systematic use of drug-eluting stents (DES) for the treatment of de novo coronary lesions at one year.
The trial was designed to test whether a stent-minimizing approach could achieve outcomes comparable to standard DES implantation.
- 62 participating sites across 12 countries in Europe and Asia
- Drug-eluting stents remain the mainstay of PCI, but are associated with a persistent annual 2–4% rate of very-late adverse cardiovascular events
Author's summary: Non-inferiority of drug-eluting balloon to standard-of-care.
More News
- Reneé Rapp Is Officially Heading Down Under Next Year - Star Observer
- The Sundarbans: Our shield against climate change
- Lahti, Finland chooses most beautiful building as city celebrates 120th anniversary - thisisFINLAND
- The price of going cashless
- Why Impact Investing Might Collapse and How to Stop It (SSIR)
- Obituaries – Week of Oct. 27, 2025 - The Observer
- MLB: Last time each team won the World Series
- Mike Brown is quickly reaching a crushing realization Knicks fans already knew
- The Coming Dementia Crisis—and the Cost of Doing Nothing
- Britain’s failing state is handing Farage win after win